Status:
NOT_YET_RECRUITING
Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma
Lead Sponsor:
University of Cologne
Conditions:
Hodgkin Lymphoma (Category)
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET/CT)...
Eligibility Criteria
Inclusion
- Histologically confirmed first diagnosis of cHL
- Advanced-stage disease: stage IIB with large mediastinal mass and/or extranodal lesions or stage III or IV
- No previous treatment for HL with the exception of steroid prephase
- Confirmed HIV infection with CD4 counts ≥ 150/μL at registration or \> 250/μL at any time within 8 months prior to HL diagnosis
- Continuation of antiretroviral treatment (ART) / Initiation of ART in patients who are ART-naive
- Age: 18-60 years
Exclusion
- Previous malignancy during last 5 years or active malignancy, prior chemotherapy or radiotherapy which precludes protocol treatment
- Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma
- Multi-drug resistant HIV infection or concurrent AIDS-defining conditions
- Pregnancy or breastfeeding
Key Trial Info
Start Date :
August 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2030
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT06919679
Start Date
August 1 2025
End Date
January 1 2030
Last Update
April 9 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.